File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy

TitleMycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy
Authors
KeywordsIgA nephropathy
Interleukin-6
Mesangial binding
Mycophenolate mofetil
Polymeric IgA
Proteinuria
Remission
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ki/index.html
Citation
Kidney International, 2005, v. 68 n. 2, p. 802-812 How to Cite?
AbstractBackground. Mycophenolate mofetil (MMF) is increasingly used to treat primary glomerulopathies. Its effectiveness in IgA nephropathy (IgAN) remains unclear. Methods. Forty IgAN patients with persistent proteinuria (>1 g/24 hours) despite conventional treatment with blockers of the renin-angiotensin system were randomized to receive MMF for 24 weeks (group 1) or continue conventional therapy (group 2), and followed for 72 weeks. The primary end point was reduction of proteinuria by 50% or more over entry level. Results. Sixteen patients (80%) in group 1 versus six patients (30%) in group 2 reached the primary end point (P = 0.0019). Time-averaged change in proteinuria showed a significant decline in group 1, while control subjects displayed a modest rise (P = 0.003). By 72 weeks, the mean proteinuria was 62.0 ± 7.7% (P = 0.003) and 120.5 ± 14.1% (P = 0.351) that of the corresponding baseline value in group 1 and group 2, respectively. There was concomitant increase in serum albumin and decrease in serum IgA levels in group 1 but not group 2 patients. Baseline histologic grades, blood pressure control, and the rates of change in serum creatinine and creatinine clearance were not different between the two groups. Normalization in binding of polymeric IgA to cultured mesangial cells and serum interleukin-6 (IL-6) levels, which sustained to study end, was observed in group 1 but not group 2 subjects. Conclusion. In selected patients with IgAN, MMF is effective in lowering proteinuria and ameliorating some of the putative pathogenetic abnormalities. © 2005 by the International Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/78261
ISSN
2015 Impact Factor: 7.683
2015 SCImago Journal Rankings: 3.181
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, Sen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorChan, LYYen_HK
dc.contributor.authorLui, YHen_HK
dc.contributor.authorTang, CSOen_HK
dc.contributor.authorKan, CHen_HK
dc.contributor.authorHo, YWen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2010-09-06T07:40:55Z-
dc.date.available2010-09-06T07:40:55Z-
dc.date.issued2005en_HK
dc.identifier.citationKidney International, 2005, v. 68 n. 2, p. 802-812en_HK
dc.identifier.issn0085-2538en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78261-
dc.description.abstractBackground. Mycophenolate mofetil (MMF) is increasingly used to treat primary glomerulopathies. Its effectiveness in IgA nephropathy (IgAN) remains unclear. Methods. Forty IgAN patients with persistent proteinuria (>1 g/24 hours) despite conventional treatment with blockers of the renin-angiotensin system were randomized to receive MMF for 24 weeks (group 1) or continue conventional therapy (group 2), and followed for 72 weeks. The primary end point was reduction of proteinuria by 50% or more over entry level. Results. Sixteen patients (80%) in group 1 versus six patients (30%) in group 2 reached the primary end point (P = 0.0019). Time-averaged change in proteinuria showed a significant decline in group 1, while control subjects displayed a modest rise (P = 0.003). By 72 weeks, the mean proteinuria was 62.0 ± 7.7% (P = 0.003) and 120.5 ± 14.1% (P = 0.351) that of the corresponding baseline value in group 1 and group 2, respectively. There was concomitant increase in serum albumin and decrease in serum IgA levels in group 1 but not group 2 patients. Baseline histologic grades, blood pressure control, and the rates of change in serum creatinine and creatinine clearance were not different between the two groups. Normalization in binding of polymeric IgA to cultured mesangial cells and serum interleukin-6 (IL-6) levels, which sustained to study end, was observed in group 1 but not group 2 subjects. Conclusion. In selected patients with IgAN, MMF is effective in lowering proteinuria and ameliorating some of the putative pathogenetic abnormalities. © 2005 by the International Society of Nephrology.en_HK
dc.languageengen_HK
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ki/index.htmlen_HK
dc.relation.ispartofKidney Internationalen_HK
dc.subjectIgA nephropathyen_HK
dc.subjectInterleukin-6en_HK
dc.subjectMesangial bindingen_HK
dc.subjectMycophenolate mofetilen_HK
dc.subjectPolymeric IgAen_HK
dc.subjectProteinuriaen_HK
dc.subjectRemissionen_HK
dc.titleMycophenolate mofetil alleviates persistent proteinuria in IgA nephropathyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0085-2538&volume=68&issue=2&spage=802&epage=812&date=2005&atitle=Mycophenolate+mofetil+alleviates+persistent+proteinuria+in+IgA+nephropathyen_HK
dc.identifier.emailTang, S: scwtang@hku.hken_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityTang, S=rp00480en_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1523-1755.2005.00460.xen_HK
dc.identifier.scopuseid_2-s2.0-26944490400en_HK
dc.identifier.hkuros121282en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-26944490400&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume68en_HK
dc.identifier.issue2en_HK
dc.identifier.spage802en_HK
dc.identifier.epage812en_HK
dc.identifier.isiWOS:000230342500040-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTang, S=7403437082en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridChan, LYY=8108378300en_HK
dc.identifier.scopusauthoridLui, YH=36914472600en_HK
dc.identifier.scopusauthoridTang, CSO=8681865300en_HK
dc.identifier.scopusauthoridKan, CH=8974503800en_HK
dc.identifier.scopusauthoridHo, YW=7402555047en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.citeulike249695-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats